Summaries of health policy coverage from major news organizations
Bristol-Myers Squibb Submits New Drug Application for Experimental Protease Inhibitor Atazanavir
Bristol-Myers Squibb has submitted a new drug application to the FDA for atazanavir, an investigational protease inhibitor that is currently in Phase III clinical trials. The application contains data from clinical trials involving more than 2,400 participants. Atazanavir, which has the potential for once-daily administration, is currently available through an early access program to patients who have experienced treatment failure with other antiretroviral drugs (BMS release, 12/20).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.